Skip to contentA
Amneal Pharmaceuticals, Inc.
A
AMRXAmneal Pharmaceuticals, Inc. Q2 2026 · 10-Q
Revenue$796.20M$796.20M+9.9% vs Q2 2025 Net Income$57.66M$57.66M+157.2% vs Q2 2025 EPS Diluted$0.18$0.18+157.1% vs Q2 2025 Gross Profit$334,508,000+16.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amneal Pharmaceuticals, Inc. · CIK 1723128 · Engraved from SEC EDGAR
Operating Cash Flowderived-$21,244,000N/M Free Cash Flowderived-$51,941,000N/M Margins · derivedGross margin42.0%+2.5 pt vs Q2 2025
Operating margin16.3%+0.9 pt vs Q2 2025
Net margin7.2%+4.1 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 6, 2026 · 37 d after period end